Research and development of innovative therapeutics for the treatment of neurofibromatosis is receiving an increasing amount of attention from key companies. In addition, regulatory authorities are providing robust support for clinical research, which is anticipated to be a primary factor driving growth in the worldwide neurofibromatosis treatment medicines market. For instance, in October 2019, SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, initiated the Phase 2b ReNeu clinical trial to evaluate the mirdametinib (formerly PD-0325901), an oral, small molecule designed to inhibit MEK1 and MEK2, in children and adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NF1-PN). For the treatment of neurofibromatosis type 1 (NF1), the European Commission granted Orphan Drug Designation to SpringWorks Therapeutics' mirdametinib (previously known as PD-0325901) in the month of July 2019. Mirdametinib is an oral, small molecule inhibitor of MEK1 and MEK2 and can be taken by mouth.
The global Neurofibromatosis Treatment Drugs Market is estimated to be valued at US$ 8,801.0 million in 2020 and is expected to exhibit a CAGR of 13.40% during the forecast period (2020-2027).
Market Players in the Neurofibromatosis Treatment Drugs Industry:
1. AstraZeneca Plc.
Teva Pharmaceutical Industries Ltd.,was founded in 1999 and it’s Cambridge, United Kingdom. The company operates in 108 countries. In 2020 · AstraZeneca and MSD are jointly developing and commercialising Koselugo globally and submitted a marketing authorisation application in NF1.
More Insights: Depressive Disorder Treatment Industry
*Definition- There are three types of Neurofibromatosis; Neurofibromatosis type 1, Neurofibromatosis type 2, and Schwannomatosis. Neurofibromatosis type (NF) 1 is a common monogenic disorder of neurocutaneous tissue growth that arises secondary to mutations in the tumor suppressor gene NF1.
